FDA Cracks Down on Compounded Weight Loss Drugs: What’s Next for Hims & Hers and the GLP-1 Market? The U.S. Food and Drug Administration (FDA) is taking a firm stance against companies marketing non-FDA-approved compounded drugs, particularly those in the GLP-1 class used for weight loss and diabetes management. This action, announced February 6, 2026, … Read more
The Statin Story: Beyond the Headlines, What’s Next for Heart Health? For decades, statins have been a cornerstone of cardiovascular disease prevention. Yet, despite their proven benefits – cutting “bad” cholesterol and reducing heart attack and stroke risk by roughly 25% – uptake remains surprisingly low, and adherence is a persistent challenge. Recent research, including … Read more
The Rise of Compounded Wegovy: A Glimpse into the Future of Weight Loss & Pharma The recent move by Hims & Hers to offer a compounded version of Wegovy, Novo Nordisk’s blockbuster weight loss drug, isn’t just a business decision – it’s a potential earthquake in the pharmaceutical landscape. Novo Nordisk’s swift accusation of “illegal … Read more
The Eczema Treatment Landscape: Beyond Dupixent and Ebglyss Nektar Therapeutics’ upcoming Phase 2 maintenance results for rezpeg in moderate-to-severe eczema (atopic dermatitis) are arriving at a pivotal moment. With the stock down over 40% since November, investors are keenly watching for data that could redefine the risk-reward profile. But this isn’t just about one company; … Read more
Vaccine Hesitancy Among Older Adults: A Growing Concern and What It Means for the Future A recent national survey from the University of Michigan’s National Poll on Healthy Aging paints a concerning picture: vaccination rates against both influenza and COVID-19 are lagging among individuals aged 50 and older. The data reveals that 42% haven’t received … Read more
Pfizer’s Pivot: Navigating a Post-COVID World and the Future of Pharma Pfizer’s recent fourth-quarter earnings report, while exceeding Wall Street expectations, paints a clear picture: the era of blockbuster COVID-19 revenue is waning. The company is now aggressively shifting its focus, and its future hinges on strategic acquisitions, cost-cutting measures, and navigating a complex landscape … Read more
The Looming Shadow Over CAR-T: Long-Term Risks and the Future of Autoimmune Therapies The FDA is signaling a critical shift in how it evaluates CAR-T cell therapies, not just for cancer, but increasingly for autoimmune diseases. A recent op-ed in the Annals of Internal Medicine, penned by FDA officials, highlights a growing concern: the potential … Read more
The Obesity Drug Revolution: How Medicare Coverage and Trump’s Plan Could Reshape the Market The landscape of obesity treatment is poised for a dramatic shift. Eli Lilly CEO Dave Ricks recently signaled that upcoming Medicare coverage, coupled with pricing agreements struck with the Trump administration, could be a game-changer for the rollout of their experimental … Read more
The Revolving Door in Biotech: Why CMO Moves Signal Bigger Trends The recent appointment of Nick Vlahakis as Chief Medical Officer at Magnet Biomedicine, following his tenure at CohBar, isn’t just a personnel shift. It’s a microcosm of a larger trend: increased movement at the executive level within the pharmaceutical and biotechnology industries. This constant … Read more
Medicare Drug Price Negotiation: A Turning Tide for Healthcare Costs? The recent announcement by the Trump administration – adding 15 drugs to the Medicare price negotiation list, crucially including those administered in doctor’s offices – marks a significant shift in the landscape of pharmaceutical pricing. While framed by the administration as building on voluntary agreements, … Read more